On April 15, 2021 Emergent BioSolutions Inc. (NYSE: EBS) reported that it will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the second quarter of 2021, and financial outlook for full year 2021 (Press release, Emergent BioSolutions, APR 15, 2021, View Source [SID1234578084]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This conference call can be accessed live by telephone or by webcast:

A replay of the call can be accessed from the Emergent website.

On April 15, 2021 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported that the company plans to issue a pre-market press release and conduct a webcast on Friday, April 16, 2021, to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib (IDE196) as monotherapy and darovasertib and binimetinib combination in patients with metastatic uveal melanoma (MUM) (ClinicalTrials.gov Identifier: NCT03947385) (Press release, Ideaya Biosciences, APR 15, 2021, View Source [SID1234578101]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IDEAYA will host a Darovasertib Investor Day, including a conference call and webcast with participation of leading clinical investigators, at 8:00 a.m. ET on Friday, April 16, 2021. The link to the webcast of the conference call will be posted on the Investor Relations Events section of the Company’s website at: View Source The update may also be accessed by dialing 1-866-248-8441 (domestic) or 1-720-452-9102 (international) five minutes prior to the start of the call and providing the passcode 2793795. An archived replay will be accessible for 90 days following the event.

IDEAYA also announced the International Nonproprietary Name (INN) for IDE196 is "darovasertib" as registered with the World Health Organization (WHO)’s Programme and Classification of Medical Products.

On April 15, 2021 Race Oncology Limited ("Race") reported to share details of a recent scientific publication in the prestigious journal Nature Communication, confirming Bisantrene is a highly effective inhibitor of the Fat Mass and Obesity associated protein (FTO)1 (Press release, Race Oncology, APR 15, 2021, View Source [SID1234578162]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This independent work was performed by a research team at the University of Chicago led by prominent Professors Chuan He and Yu-Ying He, and builds on the original identification of Bisantrene as a potent FTO inhibitor by Professor Chen and his team at the City of Hope Hospital in 20202. Prof. Chuan He’s team was the first to identify FTO as a m6A RNA demethylase3 and its involvement in many cancers.

In this new work, the University of Chicago team has identified that FTO plays a critical role in the development of skin cancers caused by low-level arsenic exposure (which promotes tumour growth) and that Bisantrene-targeted inhibition of FTO limits the growth of these skin cancers in both cell culture and mice.

The importance of this work is highlighted by the ongoing replication crisis in cancer research where many of the most exciting discoveries have not been able to be repeated in independent laboratories4. Independent confirmation of Bisantrene’s ability to target FTO further supports the clinical potential of Race’s Pillar 1 program (ASX announcements: 30 November 2020).

On April 15, 2021 AltruBio Inc. ("AltruBio" or "the Company"), a clinical stage biotech company, reported the completion of a $63 million Series A financing round (Press release, AltruBio, APR 15, 2021, View Source [SID1234578066]). The round was led by aMoon with new investors including BVF Partners L.P. (BVF), CAM Capital, and other new and existing investors joining the syndicate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AltruBio’s President & CEO, Dr. Judy Chou stated: "We are honored to have this strong group of investors join us, marking our steady growth and transformation into a truly promising biotech company with great chances of creating value for patients and all our stakeholders. The investors’ experience and support will enable the Company to leverage our PSGL-1 immune checkpoint regulator program across multiple indications, realizing our ‘pipeline in a product’ vision, and accelerating our ability to bring solutions to patients in need. The strength of this financing validates the renewal and rebuilding of the Company and further validates our science within the biotech industry."

The Company has successfully executed on a strategic shift over the past year, recruiting a new Board of Directors comprised of internationally recognized biotech industry luminaries with experience across the board in drug development and transitioning the leadership to a new President & CEO, in industry veteran Dr. Judy Chou, who joined the company after leaving Bayer where she was the global head of biotech. Under her leadership, AltruBio has implemented a new focus on its novel PSGL-1 program for immunological diseases, and the Company has now secured the funds to continue advancing the program. Recently, the company has received Fast Track Designation from the FDA for the lead asset neihulizumab (AbGn-168H) in steroid refractory acute graft-versus-host disease (SR-aGVHD).

Dr. Gur Roshwalb, MD, MBA, aMoon’s partner leading the investment added, "We view this as a great opportunity to invest in experienced leadership and unique and proven science. With the backing of an all-star board of directors, Dr. Chou has been taking all the right steps to refocus and lead the company towards a new strategic direction. The PSGL-1 program has the potential to serve as a platform to treat many different T-cell mediated, immunological diseases, offering a new solution to patients without adequate options."

On April 15, 2021 Invitae Corporation (NYSE: NVTA), a leading medical genetics company, reported research showing one in six people with colorectal cancer harbor genetic changes that are known to substantially increase the risk for cancer, especially in patients who were younger when diagnosed (Press release, Invitae, APR 15, 2021, View Source [SID1234578085]). The findings are the latest from a landmark study of genetic testing across many solid tumor cancers and were presented at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

"Colorectal cancer is one of the most common types of cancer. Recently we’ve seen an unfortunate increase in incidence among people younger than 50 years old. Improving our understanding of who is at risk and implementing appropriate screening strategies is essential to ensuring these cancers are caught and treated earlier when outcomes are typically better," said Robert Nussbaum, M.D., chief medical officer of Invitae. "Access to information about inherited risk factors is also important after diagnosis, not only for the patients themselves in whom a change in treatment was made in more than 10 percent of patients based on genetic test results, but also in alerting other family members of the need to be tested to see if they are also at increased risk and need more intensive surveillance to catch cancer early and prevent more serious disease."

The study evaluated the utility of universal multigene panel testing and found the use of multigene panel testing in colorectal cancer was associated with an increased detection of heritable mutations over guideline-based testing. In the study, 361 colorectal cancer patients received germline genetic testing using a panel that included more than 80 genes linked to increased cancer risk. Cancer-linked genetic changes were found in 15.5% (n=56) of patients predominantly in moderate and high penetrance cancer susceptibility genes such as APC, BRCA2 and TP53. The median age of patients in the study was 57 years, 43.5% were female, 82% were white and 38.2% had stage IV disease.

Younger age at diagnosis was associated with a higher likelihood of finding genetic changes linked to increased cancer susceptibility. Research from the American Cancer Society has shown rates have been increasing since the mid-1980s in adults ages 20-39 years and since the mid-1990s in adults ages 40-54 years, with younger age groups experiencing the steepest increase.